Scalper1 News
Piper Jaffray placed its bets in the biotech M&A speculation game Friday, saying that Gilead Sciences (GILD) could acquire Incyte (INCY) or Bristol-Myers Squibb (BMY) but probably wouldn’t be as interested in Vertex Pharmaceuticals (VRTX). In a report reviewing M&A in the biopharma sector, analyst Joshua Schimmer wrote that “the best fit for Gilead is a derisked, later-stage asset or collection of assets, particularly in light of the company’s Scalper1 News
Scalper1 News